ライフサイエンスコーパス: dimethylarginine

1 ensitivity C-reactive protein and asymmetric dimethylarginine).

2 characteristic of symmetric omega-N(G),N(G')-dimethylarginine.

3 ethylarginine and symmetric omega-N(G),N(G')-dimethylarginine.

4 ogenous inhibitors, asymmetric and symmetric dimethylarginine.

5 y enzyme capable of metabolizing both of the dimethylarginines.

6 ns contain both symmetrical and asymmetrical dimethylarginines.

7 Asymmetric dimethylarginine (10 microM) or native low-density lipop

8 nitric oxide synthase inhibitor asymmetrical dimethylarginine (-28% versus +0.2%) in treatment versus

9 c arginines in these domains are modified to dimethylarginines, a common modification of unknown func

10 Asymmetric dimethylarginine (ADMA) and homocysteine are mechanistic

11 Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA)

12 itric oxide synthase inhibitors asymmetrical dimethylarginine (ADMA) and monomethyl-l-arginine.

13 The endogenous methylarginines, asymmetric dimethylarginine (ADMA) and N (G)-monomethyl- l-arginine

14 thylated arginines (MA) including asymmetric dimethylarginine (ADMA) and N(G)-methyl-l-arginine (NMA)

15 The endogenous methylarginines asymmetric dimethylarginine (ADMA) and N(G)-monomethyl-L-arginine (

16 The NOS inhibitors asymmetric dimethylarginine (ADMA) and N-monomethylarginine are met

17 ylated arginines (MAs), including asymmetric dimethylarginine (ADMA) and NG-methyl-L-arginine (L-NMMA

18 inine intravenous infusion and on asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (

19 cells: monomethylarginine (MMA), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (

20 Increased levels of asymmetric dimethylarginine (ADMA) are associated with endothelial

21 ast growth factor 23 (FGF-23) and asymmetric dimethylarginine (ADMA) are associated with progression

22 endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) circulates in plasma, and its co

23 Elevated levels of asymmetric dimethylarginine (ADMA) correlate with risk factors for

24 ht to determine if a reduction in asymmetric dimethylarginine (ADMA) enhances endothelial regeneratio

25 s of the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) in the hypoxia-induced pulmonary

26 e have recently demonstrated that asymmetric dimethylarginine (ADMA) induces the translocation of end

27 We sought to determine whether asymmetric dimethylarginine (ADMA) inhibits nitric oxide (NO) elabo

28 Asymmetric dimethylarginine (ADMA) is an endogenous competitive inh

29 Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of ni

30 Asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of ni

31 Plasma asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of ni

32 Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO

33 Asymmetric dimethylarginine (ADMA) is an endogenous metabolite.

34 and the inhibitor of NO synthesis asymmetric dimethylarginine (ADMA) is increased.

35 mpact of statin therapy on plasma asymmetric dimethylarginine (ADMA) levels has not been conclusively

36 Asymmetric-dimethylarginine (ADMA) limits NO production by inhibiti

37 endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) were measured with liquid chroma

38 ting the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA), a cardiotoxic hormone whose eff

39 DAH1 is a key catabolic enzyme of asymmetric dimethylarginine (ADMA), a major endogenous nitric-oxide

40 Elevated blood concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitr

41 art by elevating plasma levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitr

42 Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitr

43 Both asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO p

44 late the metabolism or release of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO s

45 or to endothelial pathobiology is asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synt

46 Increased levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synt

47 Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synt

48 ively determined plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synt

49 or to endothelial pathobiology is asymmetric dimethylarginine (ADMA), an endogenous NO synthase inhib

50 essed associations with arginine, asymmetric dimethylarginine (ADMA), and hemolysis.

51 morning for soluble CD40 ligand, asymmetric dimethylarginine (ADMA), and nitrotyrosine levels, as we

52 generates monomethylarginine and asymmetric dimethylarginine (ADMA), but not symmetric dimethylargin

53 rs, total homocysteine (tHcy) and asymmetric dimethylarginine (ADMA), correlate with decreased levels

54 assayed for endothelin 1 (ET-1), asymmetric dimethylarginine (ADMA), intercellular adhesion molecule

55 hibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA), is elevated in patients with ty

56 arginine, citrulline, ornithine, asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDM

57 d raised plasma concentrations of asymmetric dimethylarginine (ADMA), the endogenous inhibitor of end

58 Asymmetric dimethylarginine (ADMA), which inhibits NO synthase, is

59 s nitric-oxide synthase inhibitor asymmetric dimethylarginine (ADMA).

60 MT7 into a type I PRMT, producing asymmetric dimethylarginine (ADMA).

61 ic oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA).

62 synthase has been characterized: asymmetric dimethylarginine (ADMA).

63 evels of l-arginine and increased asymmetric dimethylarginine (ADMA).

64 We focused on asymmetric dimethylarginine (ADMA, the endogenous inhibitor of nitr

65 CS patients had higher levels of asymmetric dimethylarginine (ADMA; P<0.0001), symmetric dimethylarg

66 Asymmetric and symmetric dimethylarginines (ADMA and SDMA) impair nitric oxide bi

67 vels of circulating asymmetric and symmetric dimethylarginines (ADMA and SDMA) predict and potentiall

68 s nitric oxide synthase inhibitor asymmetric dimethylarginine [ADMA, via inhibition of dimethylargini

69 omplex), endothelial dysfunction (asymmetric dimethylarginine [ADMA]), and platelet-derived inflammat

70 ginine, citrulline, asymmetric and symmetric dimethylarginine, alongside decreases in sphingolipids,

71 Asymmetric dimethylarginine also stimulated MCP-1 formation by endo

72 lipoprotein AI and high levels of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxid

73 C-reactive protein), or levels of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxid

74 pected to lead to accumulation of asymmetric dimethylarginine and inhibition of NOS.

75 he methylated proteins showed that symmetric dimethylarginine and relatively small amounts of monomet

76 f the molecules naturally contain asymmetric dimethylarginine and/or monomethylarginine.

77 2 and subsequent impairment in metabolism of dimethylarginines and BAIB caused by HNF4alpha deficienc

78 entalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all produc

79 midine, xanthine, uracil, betaine, symmetric dimethylarginine, and asymmetric-dimethylarginine), were

80 t increases in myeloperoxidase, asymmetrical dimethylarginine, and cardiac fibrosis.

81 Choline, dimethylarginine, arginine, valine, proline, serine, his

82 CARM1 catalyzed formation of N(G),N(G)-dimethylarginine (asymmetric) but little or no N(G),N'(G

83 substrates, to form NG-monomethyl and NG,NG-dimethylarginine (asymmetric).

84 othelial cell adhesion molecule, symmetrical dimethylarginine, asymmetrical dimethylarginine, high-se

85 The two types of dimethylarginines can lead to distinct biological output

86 showed a significant increase of asymmetric dimethylarginine concentration in plasma (1.41 micromol/

87 (PZN), a polyheterocyclic, N(alpha),N(alpha)-dimethylarginine-containing antibiotic, harbors remarkab

88 ethylarginine and asymmetric omega-N(G),N(G)-dimethylarginine derivatives on the recombinant glycine-

89 biologically inactive stereoisomer symmetric dimethylarginine did not inhibit NO release.

90 nine whose cellular levels are controlled by dimethylarginine dimethylamino-hydrolase (DDAH).

91 Dimethylarginine-dimethylamino-hydrolase protein express

92 both decreased breakdown (decreased hepatic dimethylarginine-dimethylamino-hydrolase) and/or increas

93 inhibitor, undergoes hepatic metabolism via dimethylarginine-dimethylamino-hydrolase, and is derived

94 ic dimethylarginine [ADMA, via inhibition of dimethylarginine dimethylaminohydrolase (DDAH) activity]

95 minated largely through active metabolism by dimethylarginine dimethylaminohydrolase (DDAH) and thus

96 termine whether overexpression of the enzyme dimethylarginine dimethylaminohydrolase (DDAH) could enh

97 Dimethylarginine dimethylaminohydrolase (DDAH) enzymes a

98 The enzyme dimethylarginine dimethylaminohydrolase (DDAH) hydrolyse

99 In mammals, the enzyme dimethylarginine dimethylaminohydrolase (DDAH) is implic

100 hesized that lowering ADMA concentrations by dimethylarginine dimethylaminohydrolase (DDAH) overexpre

101 Dimethylarginine dimethylaminohydrolase (DDAH) regulates

102 To clarify this issue, we crossed dimethylarginine dimethylaminohydrolase (DDAH) transgeni

103 The activity, but not the expression, of dimethylarginine dimethylaminohydrolase (DDAH) was reduc

104 a corresponding increase in the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzym

105 ntitumor therapeutics, as have inhibitors of dimethylarginine dimethylaminohydrolase (DDAH), an enzym

106 bstituted arginine-modifying enzymes such as dimethylarginine dimethylaminohydrolase (DDAH), arginine

107 sed to inhibit the catabolic enzyme of ADMA, dimethylarginine dimethylaminohydrolase (DDAH), but the

108 ADMA is metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), the acti

109 lled by two isoforms of its catabolic enzyme dimethylarginine dimethylaminohydrolase (DDAH), the dysr

110 was associated with the reduced activity of dimethylarginine dimethylaminohydrolase (DDAH), the enzy

111 vely metabolized by the intracellular enzyme dimethylarginine dimethylaminohydrolase (DDAH), which ca

112 endothelial cells (ECV304) and on the enzyme dimethylarginine dimethylaminohydrolase (DDAH), which de

113 inine is eliminated largely by the action of dimethylarginine dimethylaminohydrolase (DDAH), which ex

114 its NO synthase, is inactivated by N(G),N(G)-dimethylarginine dimethylaminohydrolase (DDAH).

115 methylarginine are metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH).

116 abel for the nitric oxide controlling enzyme dimethylarginine dimethylaminohydrolase (DDAH).

117 The enzymes dimethylargininase [dimethylarginine dimethylaminohydrolase (DDAH); EC 3.5.3

118 sociated with a reduction in the activity of dimethylarginine dimethylaminohydrolase (DDAH, the enzym

119 ne deiminase (PaAgDI), and N(omega),N(omega)-dimethylarginine dimethylaminohydrolase (PaDDAH) indicat

120 Dimethylarginine dimethylaminohydrolase 1 (DDAH1) degrad

121 treatment led to proteolytic degradation of dimethylarginine dimethylaminohydrolase 2, which catabol

122 itric oxide synthase [eNOS], Rho-kinase, and dimethylarginine dimethylaminohydrolase [DDAH]) were ana

123 Reports have shown that dimethylarginine dimethylaminohydrolase activity is down

124 ysregulation of the ADMA-metabolizing enzyme dimethylarginine dimethylaminohydrolase I (DDAH I) plays

125 The enzyme dimethylargininase (also known as dimethylarginine dimethylaminohydrolase or DDAH; EC 3.5.

126 crease ADMA because they bind to and inhibit dimethylarginine dimethylaminohydrolase, the enzyme that

127 co-workers to operate in the related enzyme dimethylarginine dimethylaminohydrolase, was further exp

128 ed higher amounts of ADMA-degradation enzyme dimethylarginine dimethylaminohydrolase-1 (but similar a

129 h the FXR agonist GW4064, we have identified dimethylarginine dimethylaminohydrolase-1 (DDAH1) as an

130 Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is a m

131 verexpression of the ADMA-hydrolyzing enzyme dimethylarginine dimethylaminohydrolase-1 (DDAH1), we te

132 Dimethylarginine dimethylaminohydrolase-1 transgenic (TG

133 We further observed myocardial levels of dimethylarginine dimethylaminohydrolase-1 were increased

134 ethyltransferases (PRMTs) and is degraded by dimethylarginine dimethylaminohydrolase.

135 le of ADMA, and the enzymes metabolizing it, dimethylarginine dimethylaminohydrolases (DDAH) in the r

136 ADMA levels are controlled by dimethylarginine dimethylaminohydrolases (DDAHs), cytoso

137 Dimethylarginines (DMA) interfere with nitric oxide form

138 , symmetrical dimethylarginine, asymmetrical dimethylarginine, high-sensitivity troponin T, and cysta

139 ethylarginine and symmetric omega-N(G),N(G')-dimethylarginine in a variety of proteins.

140 ponsible for the deposition of the symmetric dimethylarginine in mammalian cells.

141 talyzes the formation of asymmetric (type I) dimethylarginine in vitro.

142 me functions to modify specific arginines to dimethylarginines in the arginine- and glycine-rich doma

143 Asymmetric dimethylarginine increases endothelial oxidative stress

144 Asymmetric dimethylarginine-induced monocyte binding was diminished

145 Asymmetric dimethylarginine is an endogenous inhibitor of nitric ox

146 Asymmetric dimethylarginine is eliminated largely by the action of

147 nt competitive interaction between symmetric dimethylarginine level and c-terminal FGF-23 level for t

148 tients with normal renal function, symmetric dimethylarginine levels inversely correlated with mean a

149 Symmetric dimethylarginine levels were increased in serum and frac

150 ell adhesion molecule (VCAM), and asymmetric dimethylarginine levels were measured.

151 Asymmetric dimethylarginine may be an endogenous proatherogenic mol

152 Elevated dimethylarginines may serve as important biological mark

153 nts revealed the presence of the symmetrical dimethylarginine modification catalyzed by PRMT5 associa

154 ansferase (PRMT)-1, and nuclear asymmetrical dimethylarginine modification was increased with LRP6-VK

155 enzyme responsible for generating symmetric dimethylarginine modifications on the carboxyl-terminal

156 nce contexts, and identification of isomeric dimethylarginine modifications.

157 However, symmetrical dimethylarginine-modified proteins were not detected at

158 ting discrete biological roles for mono- and dimethylarginine-modified proteins.

159 We show that SMN binds preferentially to the dimethylarginine-modified RG domains of SmD1 and SmD3.

160 thylarginine, not asymmetric omega-N(G),N(G)-dimethylarginine or symmetric omega-N(G),N(G')-dimethyla

161 dimethylarginine (ADMA; P<0.0001), symmetric dimethylarginine (P<0.0001), monomethylarginine (P=0.000

162 Asymmetric dimethylarginine plays a role in endothelial dysfunction

163 In the absence of the omega-NG, NG-[3H]dimethylarginine product of the RMT1 methyltransferase,

164 peptide (r=0.25, P=0.001), and asymmetrical dimethylarginine (r=0.32, P<0.001).

165 The arginine-to-dimethylarginine ratio is associated with severe sepsis,

166 We hypothesized that the arginine-to-dimethylarginine ratio is reduced in patients with sever

167 The arginine-to-dimethylarginine ratio may be a useful biomarker, and in

168 The arginine-to-dimethylarginine ratio was correlated with Acute Physiol

169 The arginine-to-dimethylarginine ratio was correlated with the urinary n

170 The arginine-to-dimethylarginine ratio was higher in control subjects vs

171 A declining arginine-to-dimethylarginine ratio was independently associated with

172 hat can result in the formation of symmetric dimethylarginine residues as observed previously in myel

173 the formation of asymmetric omega-N(G),N(G)-dimethylarginine residues by transferring methyl groups

174 rupted is viable, but the level of NG,NG-[3H]dimethylarginine residues detected in intact cells incub

175 MA and their combined sum, which we termed a dimethylarginine score, were better predictors of outcom

176 RMTs, PRMT5, affects the levels of symmetric dimethylarginine (SDMA) at Arg-3 on histone H4, leading

177 levels of L-arginine, ADMA, and symmetrical dimethylarginine (SDMA) by high-performance liquid chrom

178 metric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) concentrations in conditions rep

179 Elevated symmetric dimethylarginine (SDMA) has been shown to predict cardio

180 We uncover the presence of symmetrical dimethylarginine (sDMA) on chromatoid body components an

181 mmalian enzymes capable of forming symmetric dimethylarginine (SDMA) residues as type II PRMTs.

182 spliceosomal Sm proteins contain symmetrical dimethylarginine (sDMA) residues in vivo.

183 ranslationally modified to contain symmetric dimethylarginine (sDMA) residues within their C-terminal

184 symmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and N-monomethylarginine (MMA)

185 hether ADMA, and its stereo-isomer symmetric dimethylarginine (SDMA), are increased in alcoholic hepa

186 inase, cell-free hemoglobin, ADMA, symmetric-dimethylarginine (SDMA), histidine-rich protein-2, and a

187 that catalyzes the formation of symmetrical dimethylarginine (sDMA), is a nucleolin-associated prote

188 ntly generate either asymmetric or symmetric dimethylarginine (SDMA), PRMT7 is unique in producing so

189 eferentially and directly to the symmetrical dimethylarginine (sDMA)-modified arginine- and glycine-r

190 edominantly monomethylarginine and symmetric dimethylarginine (SDMA).

191 c dimethylarginine (ADMA), but not symmetric dimethylarginine (SDMA).

192 ydrolase (DDAH) activity] and with symmetric dimethylarginine (SDMA).

193 metric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA).

194 atographed with a symmetric omega-N(G),N(G')-dimethylarginine standard.

195 ine (asymmetric) but little or no N(G),N'(G)-dimethylarginine (symmetric) and no form of methyllysine

196 Coilin contains symmetrical dimethylarginines that modulate its affinity for SMN, an

197 the level of p-cresol sulfate or asymmetric dimethylarginine to significant reductions in the levels

198 landin F(1alpha), endothelin-1, asymmetrical dimethylarginine, tumor necrosis factor-alpha, monocyte

199 vity) as well as small amounts of asymmetric dimethylarginine (type I activity).

200 methylarginine or symmetric omega-N(G),N(G')-dimethylarginine, under the conditions tested.

201 ieu contains increased amounts of asymmetric dimethylarginine, we speculate that such accumulation of

202 ric oxide oxidation products, and asymmetric dimethylarginine were abnormal in patients with PAH and

203 ls of l-arginine, arginase-1, and asymmetric dimethylarginine were measured at serial time-points.

204 amounts of monomethylarginine and asymmetric dimethylarginine were produced.

205 ansferase activity and asymmetric N(G), N(G)-dimethylarginine were reduced by 85 and 54%, respectivel

206 , symmetric dimethylarginine, and asymmetric-dimethylarginine), were also increased in urine from tum